AR117081A1 - Métodos de inactivación vírica para la fabricación continua de anticuerpos - Google Patents
Métodos de inactivación vírica para la fabricación continua de anticuerposInfo
- Publication number
- AR117081A1 AR117081A1 ARP190103352A ARP190103352A AR117081A1 AR 117081 A1 AR117081 A1 AR 117081A1 AR P190103352 A ARP190103352 A AR P190103352A AR P190103352 A ARP190103352 A AR P190103352A AR 117081 A1 AR117081 A1 AR 117081A1
- Authority
- AR
- Argentina
- Prior art keywords
- virus inactivation
- antibodies
- continuous manufacture
- inactivation methods
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
- C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13061—Methods of inactivation or attenuation
- C12N2740/13063—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Detergent Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta divulgación se relaciona con los métodos a usar en los virus de inactivación. Los métodos de inactivación del virus son para uso en la fabricación del proceso continuo de un agente biológico, tal como un anticuerpo e incluye la separación de un eluato a un tratamiento ortogonal de pH bajo y detergente de manera simultánea en donde el tiempo para la inactivación vírica se reduce. Además, el detergente se puede agregar al sistema de amortiguación en el proceso de purificación para lograr el mismo efecto. Se conserva el agente biológico en cada caso de tratamiento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767652P | 2018-11-15 | 2018-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117081A1 true AR117081A1 (es) | 2021-07-07 |
Family
ID=69024584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103352A AR117081A1 (es) | 2018-11-15 | 2019-11-14 | Métodos de inactivación vírica para la fabricación continua de anticuerpos |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP3880806A1 (es) |
| JP (1) | JP7518825B2 (es) |
| KR (1) | KR20210091709A (es) |
| CN (1) | CN113015795B (es) |
| AR (1) | AR117081A1 (es) |
| AU (1) | AU2019380308A1 (es) |
| BR (1) | BR112021006498A2 (es) |
| CA (1) | CA3119629A1 (es) |
| IL (1) | IL282944A (es) |
| MX (1) | MX2021005685A (es) |
| PE (1) | PE20211140A1 (es) |
| SG (1) | SG11202103790WA (es) |
| WO (1) | WO2020102505A1 (es) |
| ZA (1) | ZA202104083B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115873810B (zh) * | 2022-12-26 | 2024-02-09 | 苏州良辰生物医药科技有限公司 | 一种鼠白血病病毒的纯化方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994013329A1 (de) * | 1992-12-16 | 1994-06-23 | Immuno Aktiengesellschaft | Verfahren zur herstellung eines virussicheren biologischen präparates |
| IL136552A (en) * | 2000-06-05 | 2005-05-17 | Omrix Biopharmaceuticals Ltd | Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration |
| WO2008076371A2 (en) | 2006-12-15 | 2008-06-26 | Schering-Plough Ltd. | Method for replicating influenza virus in culture |
| CA2808116C (en) * | 2010-07-30 | 2016-06-07 | Pfizer Inc. | Tandem purification of proteins |
| EP3981873A1 (en) * | 2012-06-29 | 2022-04-13 | EMD Millipore Corporation | Methods for inactivating viruses during a protein purification process |
| US10188732B2 (en) | 2012-08-06 | 2019-01-29 | Biogen Ma Inc. | Methods and compositions for inactivating enveloped viruses |
| CN105722523B (zh) | 2013-11-15 | 2022-06-14 | 豪夫迈·罗氏有限公司 | 使用环保洗涤剂的病毒灭活方法 |
| EP4234569A3 (en) * | 2014-04-15 | 2023-10-18 | Boehringer Ingelheim International GmbH | Method and use for continuously inactivating a virus during manufacture of a biological product |
| WO2016207328A1 (en) * | 2015-06-24 | 2016-12-29 | Glycotope Gmbh | PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES |
-
2019
- 2019-11-14 AR ARP190103352A patent/AR117081A1/es unknown
- 2019-11-14 PE PE2021000699A patent/PE20211140A1/es unknown
- 2019-11-14 CN CN201980074580.XA patent/CN113015795B/zh active Active
- 2019-11-14 CA CA3119629A patent/CA3119629A1/en active Pending
- 2019-11-14 JP JP2021526241A patent/JP7518825B2/ja active Active
- 2019-11-14 AU AU2019380308A patent/AU2019380308A1/en active Pending
- 2019-11-14 EP EP19828357.4A patent/EP3880806A1/en active Pending
- 2019-11-14 MX MX2021005685A patent/MX2021005685A/es unknown
- 2019-11-14 WO PCT/US2019/061436 patent/WO2020102505A1/en unknown
- 2019-11-14 BR BR112021006498A patent/BR112021006498A2/pt not_active IP Right Cessation
- 2019-11-14 SG SG11202103790WA patent/SG11202103790WA/en unknown
- 2019-11-14 KR KR1020217014291A patent/KR20210091709A/ko unknown
-
2021
- 2021-05-05 IL IL282944A patent/IL282944A/en unknown
- 2021-06-14 ZA ZA2021/04083A patent/ZA202104083B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202039836A (zh) | 2020-11-01 |
| JP2022507369A (ja) | 2022-01-18 |
| EP3880806A1 (en) | 2021-09-22 |
| SG11202103790WA (en) | 2021-05-28 |
| CN113015795A (zh) | 2021-06-22 |
| CA3119629A1 (en) | 2020-05-22 |
| CN113015795B (zh) | 2024-10-01 |
| MX2021005685A (es) | 2021-07-07 |
| PE20211140A1 (es) | 2021-06-25 |
| ZA202104083B (en) | 2023-01-25 |
| JP7518825B2 (ja) | 2024-07-18 |
| IL282944A (en) | 2021-06-30 |
| US20220002679A1 (en) | 2022-01-06 |
| BR112021006498A2 (pt) | 2021-07-06 |
| KR20210091709A (ko) | 2021-07-22 |
| WO2020102505A1 (en) | 2020-05-22 |
| AU2019380308A1 (en) | 2021-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201791086A1 (ru) | Человеческие антитела против гемагглютинина вируса гриппа | |
| BR112018008326A2 (pt) | composições e métodos para o tratamento de câncer | |
| PH12019502003A1 (en) | Cyclic sulfamide compounds and methods of using same | |
| CO2017007619A2 (es) | Anticuerpos humanos contra glicoproteína del virus ébola | |
| BR112015022790A8 (pt) | molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral | |
| BR112016016916A2 (pt) | método de tratamento de angiodema hereditário (hae) | |
| BR112017001049A2 (pt) | material biocomposto anisotrópico, implantes médicos contendo o mesmo e métodos de tratamento do mesmo | |
| CO6640274A2 (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
| EA201591786A1 (ru) | Монотерапия gla для применения в лечении рака | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
| EA201692358A1 (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
| EA201891975A1 (ru) | Тиазолидные соединения для лечения вирусных инфекций | |
| ES2980846T3 (es) | Purificación de proteínas e inactivación de virus con alquilglucósidos | |
| PE20210651A1 (es) | Vacunas contra virus de la gripe y usos de las mismas | |
| EA201892448A1 (ru) | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения | |
| EA202192923A1 (ru) | Антитела и способы лечения инфекции, вызываемой вирусом гриппа а | |
| CL2017003309A1 (es) | Métodos de purificación y/o inactivación viral | |
| AR117081A1 (es) | Métodos de inactivación vírica para la fabricación continua de anticuerpos | |
| EA201500837A1 (ru) | Парвовирус свиней 5в, способы применения и вакцина | |
| CO7030958A2 (es) | Compuestos sustituidos de bencilamina, su uso en medicina, y en particular en el tratamiento de la infección del virús de la hepatitis c (vch) | |
| EA201592298A1 (ru) | Полуживая вирусная вакцина против респираторно-синцитиального вируса | |
| EA200901064A1 (ru) | Лекарственное средство для лечения гриппа у птиц | |
| EA201991927A1 (ru) | Новый иммуностимулирующий макролид | |
| BR112021006388A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero |